UCB SA (UCB.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:UCB - BE0003739530 - Common Stock
241.2 EUR
+4.8 (+2.03%)
Taking everything into account, UCB scores 6 out of 10 in our fundamental rating. UCB was compared to 54 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of UCB get a neutral evaluation. Nothing too spectacular is happening here. UCB is valued quite expensive, but it does show an excellent growth. These ratings could make UCB a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year UCB was profitable.
UCB had a positive operating cash flow in the past year.
Each year in the past 5 years UCB has been profitable.
Each year in the past 5 years UCB had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of 7.75%, UCB perfoms like the industry average, outperforming 58.49% of the companies in the same industry.
The Return On Equity of UCB (13.76%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 11.63%, UCB is in line with its industry, outperforming 58.49% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 13.79%.
The last Return On Invested Capital (11.63%) for UCB is above the 3 year average (4.35%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
UCB has a better Profit Margin (19.45%) than 73.58% of its industry peers.
UCB's Profit Margin has been stable in the last couple of years.
UCB's Operating Margin of 26.58% is fine compared to the rest of the industry. UCB outperforms 67.92% of its industry peers.
UCB's Operating Margin has declined in the last couple of years.
UCB has a better Gross Margin (73.38%) than 62.26% of its industry peers.
UCB's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UCB is still creating some value.
Compared to 1 year ago, UCB has about the same amount of shares outstanding.
Compared to 5 years ago, UCB has more shares outstanding
UCB has a better debt/assets ratio than last year.
2.2 Solvency
UCB has an Altman-Z score of 5.20. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
UCB has a better Altman-Z score (5.20) than 77.36% of its industry peers.
UCB has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as UCB would need 2.43 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.43, UCB is in the better half of the industry, outperforming 71.70% of the companies in the same industry.
UCB has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.29, UCB is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.2 |
ROIC/WACC1.5
WACC7.76%
2.3 Liquidity
A Current Ratio of 1.35 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a Current ratio (1.35) which is comparable to the rest of the industry.
A Quick Ratio of 1.01 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a Quick ratio of 1.01. This is comparable to the rest of the industry: UCB outperforms 56.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 75.41% over the past year.
Measured over the past years, UCB shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.86% on average per year.
The Revenue has grown by 25.56% in the past year. This is a very strong growth!
UCB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.60% yearly.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
3.2 Future
Based on estimates for the next years, UCB will show a very strong growth in Earnings Per Share. The EPS will grow by 29.65% on average per year.
The Revenue is expected to grow by 14.44% on average over the next years. This is quite good.
EPS Next Y55.04%
EPS Next 2Y42.89%
EPS Next 3Y38.34%
EPS Next 5Y29.65%
Revenue Next Year23.14%
Revenue Next 2Y18.72%
Revenue Next 3Y17.23%
Revenue Next 5Y14.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
UCB is valuated quite expensively with a Price/Earnings ratio of 37.57.
Compared to the rest of the industry, the Price/Earnings ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 60.38% of the companies listed in the same industry.
UCB's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.39.
Based on the Price/Forward Earnings ratio of 23.72, the valuation of UCB can be described as rather expensive.
60.38% of the companies in the same industry are cheaper than UCB, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of UCB to the average of the S&P500 Index (23.84), we can say UCB is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.57 | ||
| Fwd PE | 23.72 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 62.26% of the companies listed in the same industry.
UCB's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.59 | ||
| EV/EBITDA | 19.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UCB has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as UCB's earnings are expected to grow with 38.34% in the coming years.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y42.89%
EPS Next 3Y38.34%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.41%, which is pretty low.
Compared to an average industry Dividend Yield of 1.85, UCB has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.87, UCB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.45%.
Dividend Growth(5Y)2.45%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
19.82% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y42.89%
EPS Next 3Y38.34%
EBR:UCB (12/19/2025, 7:00:00 PM)
241.2
+4.8 (+2.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners41.89%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap46.92B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts76
Price Target257.04 (6.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
Yearly Dividend1.36
Dividend Growth(5Y)2.45%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.89%
PT rev (3m)13.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.22%
EPS NY rev (3m)2.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.57 | ||
| Fwd PE | 23.72 | ||
| P/S | 6.85 | ||
| P/FCF | 39.59 | ||
| P/OCF | 29.77 | ||
| P/B | 4.85 | ||
| P/tB | 43.16 | ||
| EV/EBITDA | 19.29 |
EPS(TTM)6.42
EY2.66%
EPS(NY)10.17
Fwd EY4.22%
FCF(TTM)6.09
FCFY2.53%
OCF(TTM)8.1
OCFY3.36%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.68
PEG (5Y)N/A
Graham Number84.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROCE | 13.73% | ||
| ROIC | 11.63% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 58.2% | ||
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% | ||
| FCFM | 17.3% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 61.48% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 16.4 | ||
| Cash Conversion | 64.17% | ||
| Profit Quality | 88.96% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 5.2 |
F-Score9
WACC7.76%
ROIC/WACC1.5
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y55.04%
EPS Next 2Y42.89%
EPS Next 3Y38.34%
EPS Next 5Y29.65%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year23.14%
Revenue Next 2Y18.72%
Revenue Next 3Y17.23%
Revenue Next 5Y14.44%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year157.14%
EBIT Next 3Y59.96%
EBIT Next 5Y40.4%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%
UCB SA / UCB.BR FAQ
What is the fundamental rating for UCB stock?
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.
What is the valuation status of UCB SA (UCB.BR) stock?
ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UCB.BR). This can be considered as Overvalued.
Can you provide the profitability details for UCB SA?
UCB SA (UCB.BR) has a profitability rating of 6 / 10.
How financially healthy is UCB SA?
The financial health rating of UCB SA (UCB.BR) is 6 / 10.
How sustainable is the dividend of UCB SA (UCB.BR) stock?
The dividend rating of UCB SA (UCB.BR) is 4 / 10 and the dividend payout ratio is 19.82%.